Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

US10399961B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Sara Frattini · Castelleone, IT
• Remko Alexander BAKKER · Biberach an der Riß, DE
• Riccardo Giovannini · Verona, IT
• Dieter Hamprecht · Verona, IT
• Iain Lingard · Monza, IT
• Alexander Pautsch · Ulm, DE
• Bernd Wellenzohn · Friedrichshafen, DE

Key dates

• Filing date: Oct 20, 2016
• Grant date: Sep 3, 2019
• Expiry date: Oct 20, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of general formula I, wherein D1 to D3, A, R1, R2, Y and n are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.